StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 07:00:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech names Dr. Marjan Farid as medical advisory board chair http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html <p>Aurion Biotech, Inc. appointed Dr. Marjan Farid as chair of its medical advisory board, the regenerative cell therapy company announced. Dr. Farid serves as Director of Cornea, Cataract, and Refractive Surgery and Clinical Professor at the Gavin Herbert Eye Institute at the University of California-Irvine.</p> <p>Dr. Farid chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery and established the UCI Severe Ocular Surface Disease Program. She serves on the Leadership Committee at ASCRS and has published research in ophthalmology while editing medical publications including "Steinert's Cataract Surgery" and "In-Office Corneal Procedures."</p> <p>"Aurion welcomes a deeply respected clinical http://www.streetinsider.com/Board+Changes/Aurion+Biotech+names+Dr.+Marjan+Farid+as+medical+advisory+board+chair/26142475.html Wed, 11 Mar 2026 07:00:22 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Press+Releases/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html <p> SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faurionbiotech.com%2F&esheet=54442616&newsitemid=20260311946988&lan=en-US&anchor=Aurion+Biotech&index=1&md5=fd0897faed66a3184428ff81968a8924" shape="rect">Aurion Biotech</a>, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS). </p><p id="news-body-cta">This press http://www.streetinsider.com/Business+Wire/Aurion+Biotech+Appoints+World+Renowned+Cornea+Surgeon+Marjan+Farid%2C+M.D.%2C+to+Chair+Medical+Advisory+Board/26142445.html Wed, 11 Mar 2026 07:00:00 -0400 A.36051233 A.50216639 ALC O.22132046 O.40834251 O.54947191 UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141654.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html Wed, 11 Mar 2026 02:55:07 -0400 ALC UBS Reiterates Buy and Top Large Cap Pick Rating on Alcon Inc. (ALC:SW) (ALC) http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html <p>UBS analyst Graham Doyle reiterated a Buy rating and CHF95.00 price target on Alcon Inc. (ALC:SW) (NYSE: ALC).</p><p>The analyst comments: "Alcon cut guidance twice last year leaving investors disappointed. But, we think the next 18 months are chock-full of 1) earnings beats, 2) guidance raises and 3) product-specific catalysts. We expect earnings beats to start on 6 May with Q1 organic growth at least 7% (guide of 5-7%). We expect upgrades to come from Q2 given the guide is likely to look infeasibly conservative at that point and would imply material market slowdown. Lastly, we anticipate several upcoming product catalysts http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+and+Top+Large+Cap+Pick+Rating+on+Alcon+Inc.+%28ALC%3ASW%29+%28ALC%29/26141655.html Wed, 11 Mar 2026 02:55:07 -0400 ALC